Pernix Therapeutics (PTX) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pernix Therapeutics Reports Second Quarter 2015 Financial Results
August 6, 2015 6:50 AM EDTRevenues Increase Over 150% Year-Over-Year
Company Provides Updated Financial Guidance
MORRISTOWN, N.J., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) ("Pernix" or "the Company"), a specialty pharmaceutical company, today announced financial results for the second quarter ended June 30, 2015. Second Quarter and Recent Business Highlights:
Treximet sales and volumes increased significantly, arresting a multi-year decline and demonstrating a clear trend reversal:o     Total prescriptions increased 10% since sampling was initiated at the end of March
o     New prescriptions increased by 15% over the same time period
o     ... More
Pernix Therapeutics Reports Second Quarter 2015 Financial Results
August 6, 2015 6:50 AM EDTRevenues Increase Over 150% Year-Over-Year
Company Provides Updated Financial Guidance
MORRISTOWN, N.J., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) ("Pernix" or "the Company"), a specialty pharmaceutical company, today announced financial results for the second quarter ended June 30, 2015. Second Quarter and Recent Business Highlights:
Treximet sales and volumes increased significantly, arresting a multi-year decline and demonstrating a clear trend reversal:o     Total prescriptions increased 10% since sampling was initiated at the end of March
o     New prescriptions increased by 15% over the same time period
o     ... More
